---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-133730"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:51:59.231774+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics enters up to $500M loan facility with Oxford Finance; $75M initial draw

## Summary
- Initial $75M funded June 4, 2025; remaining $50M from $125M first tranche drawable in 2026.
- Additional tranches: up to $175M upon milestones, plus $200M uncommitted subject to mutual agreement.
- Interest rate: greater of 1-Month Term SOFR + 4.95% and 8.70%; maturity June 2030 or 2031.
- Collateral on substantially all assets except IP; financial covenants require minimum liquidity or loan coverage ratios.
- Facility fee 0.75% of funded amount; final payment and prepayment fees apply.

## SEC filing metadata
- accession: 0001193125-25-133730
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312525133730/0001193125-25-133730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312525133730/d869940d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-133730
- JSON: https://secwatch.observer/filing/0001193125-25-133730.json
- Plain text: https://secwatch.observer/filing/0001193125-25-133730.txt

## Key facts
- Debt Financings
  Vera Therapeutics, Inc. incurred credit facility of up to $500.0 million with Oxford Finance LLC at greater of (x) the 1-Month CME Term SOFR plus 4.95% and (y) 8.70% maturing June 1, 2030, or June 1, 2031.
  - Instrument: credit facility
  - Principal: up to $500.0 million
  - Counterparty: Oxford Finance LLC
  - Rate: greater of (x) the 1-Month CME Term SOFR plus 4.95% and (y) 8.70%
  - Maturity: June 1, 2030, or June 1, 2031
  - Event: incurrence
  source text: On June 2, 2025 (the “Effective Date”), Vera Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto (collectively, the “Lenders”). The Agreement provides for term loans in an aggregate principal amount of up to $500.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312525133730/0001193125-25-133730-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.